Parental history of alzheimer's disease

1. Parental history of alzheimer's disease increases IL-18 in humans.

   “IL‐18 levels were significantly higher in Black individuals with a parental history of AD compared to Black individuals without”

   Humansin Black individualsplasman = 1,043

   Associations between parental history of Alzheimer's disease and plasma markers of immunity in a multi‐ethnic community cohort of middle‐aged adults

   AAIC 2025 abstract·26 Dec 2025

More on IL-18

1. Parental history of alzheimer's disease decreases VEGF-A in humans (-0.16, 95% CI: -0.3,-0.01).

   “VEGF‐A (‐0.16, 95% CI: ‐0.3,‐0.01), and IL‐27 (‐0.07, 95% CI: ‐0.15,0.0) compared with those without a parental history of AD”

   Humansplasman = 1,043

   Associations between parental history of Alzheimer's disease and plasma markers of immunity in a multi‐ethnic community cohort of middle‐aged adults

   AAIC 2025 abstract·26 Dec 2025

More on VEGF-A

1. Parental history of alzheimer's disease decreases G-CSF in humans (-0.2, 95% CI: -0.35,-0.04).

   “lower levels of G‐CSF (‐0.2, 95% CI: ‐0.35,‐0.04), VEGF‐A (‐0.16, 95% CI: ‐0.3,‐0.01), and IL‐27 (‐0.07, 95% CI: ‐0.15,0.0)”

   Humansplasman = 1,043

   Associations between parental history of Alzheimer's disease and plasma markers of immunity in a multi‐ethnic community cohort of middle‐aged adults

   AAIC 2025 abstract·26 Dec 2025

More on G-CSF

1. Parental history of alzheimer's disease increases eotaxin in humans (log-diff: 0.09, 95% CI: 0.01,.0.15).

   “Participants with a parental history of AD ( n = 660, mean age=54, 65% women) had higher levels of Eotaxin (log‐diff: 0.09, 95% CI: 0.01,.0.15)”

   Humansplasman = 1,043

   Associations between parental history of Alzheimer's disease and plasma markers of immunity in a multi‐ethnic community cohort of middle‐aged adults

   AAIC 2025 abstract·26 Dec 2025

More on Eotaxin